Chung Hoow Kok
Adelaide Medical School
Faculty of Health and Medical Sciences
I am a senior lecturer with an expertise in molecular cancer biology and bioinformatics in cancer, currently based at the SAHMRI and the University of Adelaide. My research focuses on utilizing artificial intelligence in chronic myeloid leukaemia, for purposes of biomarker discovery, and development of new algorithms in next-generation sequencing analysis.
-
Appointments
Date Position Institution name 2018 - ongoing Senior Bioinformatician (CML research) South Australian Health and Medical Research Institute, Adelaide 2017 - ongoing Affiliate Senior Lecturer University of Adelaide, Adelaide 2014 - 2018 Postdoctoral Researcher South Australian Health and Medical Research Institute, Adelaide 2011 - 2017 Affiliate Lecturer University of Adelaide, Adelaide -
Awards and Achievements
Date Type Title Institution Name Country Amount 2014 Fellowship RAH Mary Overton early career research fellowship Royal Adelaide Hospital Australia AUD252,000 -
Language Competencies
Language Competency Chinese (Cantonese) Can speak and understand spoken Chinese (Mandarin) Can speak and understand spoken English Can read, write, speak, understand spoken and peer review -
Education
Date Institution name Country Title 2006 - 2010 University of Adelaide Australia PhD 2005 - 2005 University of Adelaide Australia BSc(Hons) 2002 - 2004 University of Adelaide Australia BSc(Biomedical Science) -
Research Interests
-
Journals
-
Conference Papers
Year Citation 2021 Kutyna, M., Kok, C. H., Wee, L. Y., Paton, S., Chhetri, R., Thomas, D., . . . Hiwase, D. (2021). BONE MARROW MICROENVIRONMENT IN THERAPY-RELATED MYELOID NEOPLASMS IS DISTINCT FROM OTHER MYELOID NEOPLASMS, PROBABLY DRIVEN BY PRIOR CYTOTOXIC THERAPY. In LEUKEMIA RESEARCH Vol. 108 (pp. S18-S19). PERGAMON-ELSEVIER SCIENCE LTD. 2019 Kok, C. H., Liu, L., Yeung, D. T., Saunders, V. A., Dang, P., & Hughes, T. P. (2019). A Combination of CD302 gene Expression and 3-Months BCR-ABL1 Level Predicts Inferior Achievement of Deep Molecular Response in CP-CML Patients Treated with Imatinib. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
2016 Asari, K., Heatley, S. L., Sadras, T., Leclercq, T. M., Fitter, S., Kok, C. H., . . . White, D. L. (2016). In Vitro Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance Implications for Targeted Therapy. In BLOOD Vol. 128 (pp. 5 pages). San Diego, CA: AMER SOC HEMATOLOGY.
2016 Pagani, I. S., Kok, C. H., Wang, J., Saunders, V., Goyne, J., McLean, J., . . . Ross, D. M. (2016). MITOCHONDRIAL DNA MUTATIONS IDENTIFY CLONAL HETEROGENEITY IN CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA Vol. 101 (pp. 234). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. 2016 Pagani, I. S., Kok, C. H., Saunders, V., Goyne, J., McLean, J., VanderHoek, M., . . . Ross, D. M. (2016). The genomic landscape of mitochondrial DNA mutations in chronic myeloid leukaemia.. In European Journal of Human Genetics. Barcelona: Natue Publishing Group. 2015 Wang, J., Kok, C. H., Leclercq, T. M., Saunders, V. A., D'Andrea, R. J., Hughes, T. P., & White, D. L. (2015). High Peroxisome Proliferator-Activated Receptor-Gamma (PPAR gamma le) Transcriptional Activity Reduces Active Influx of Imatinib and Kinase Inhibition in CML Cells. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Kok, C. H., Leclercq, T. M., Watkins, D., Yeung, D. T., Saunders, V. A., White, D. L., & Hughes, T. P. (2015). A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2014 Vandyke, K., Mrozik, K. M., Cheong, C. M., Chow, A. W. S., Kok, C. H., Blaschuk, O., . . . Zannettino, A. C. W. (2014). Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention. In BLOOD Vol. 124 (pp. 3 pages). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS12011 Watkins, D. B., Kok, C. H., Hughes, T. P., Slader, C., D'Andrea, R., & White, D. L. (2011). Differential Lineage Involvement Between Very Low and Higher OCT-1 Activity Chronic-Phase CML Patients. In BLOOD Vol. 118 (pp. 727). San Diego, CA: AMER SOC HEMATOLOGY. 2011 Wang, J., Hughes, T. P., Kok, C. H., Saunders, V. A., Frede, A., GrootObbink, K., . . . White, D. L. (2011). Non-Steroidal Anti-Inflammatory Drugs and Imatinib; Drug Interactions That May Impact Efficacy. In BLOOD Vol. 118 (pp. 1493-1494). San Diego, CA: AMER SOC HEMATOLOGY. 2011 D'Andrea, R. J., Perugini, M., Kok, C. H., Salerno, D., Danner, S., Bardy, P. G., . . . Lewis, I. D. (2011). Methylation of a Single CpG in the GADD45A Proximal Promoter Is Associated with Poor Survival in Acute Myeloid Leukemia. In BLOOD Vol. 118 (pp. 1511). San Diego, CA: AMER SOC HEMATOLOGY. 2010 Powell, J., Thomas, D., Barry, E., Kok, C., Ma, L., To, L., . . . Guthridge, M. (2010). TARGETING CELL SURVIVAL PATHWAYS IN ACUTE MYELOID LEUKEMIA. In EXPERIMENTAL HEMATOLOGY Vol. 38 (pp. S60). Melbourne, AUSTRALIA: ELSEVIER SCIENCE INC. 2005 Wilkinson, C., Brown, A., Kok, C., Solomon, P., Goodall, G., Gonda, T., & D'Andrea, M. (2005). Expression profiling of a myeloid cell line model to identify novel transcription factors influencing myeloid cell differentiation proliferation and leukaemia. In Proceedings of 5th Australian Microarray Conference 2005 (pp. unknown). Australia: Unknown. -
Conference Items
Year Citation 2018 Heatley, S. L., Mayne, B. T., McClure, B. J., Kok, C., Sadras, T., Dang, P., . . . White, D. L. (2018). Exploring the genomic diversity of AYA and adult high-risk B-ALL cases by mRNA sequencing. Poster session presented at the meeting of 23rd Congress of European Hematology Association. Stockholm, Sweden. 2018 Heatley, S. L., McClure, B. J., Kok, C., Sadras, T., Dang, P., Galbraith, K., . . . White, D. L. (2018). Exploring the genomic diversity of adult and AYA cases with high-risk B-ALL by mRNA sequencing. Poster session presented at the meeting of NDLR. 2018 Pagani, I. S., Kok, C., Saunders, V., Schwarer, A., Hughes, T. P., White, D. L., & Ross, D. M. (2018). Association of mitochondrial DNA (mtDNA) mutations at diagnosis with treatment response in chronic myeloid leukaemia (CML) patients. Poster session presented at the meeting of NDLR. 2018 Lu, L., Kok, C., Saunders, V., Nievergall, E., White, D. L., & Hughes, T. P. (2018). TGF-α predicts TKI treated CML patients who fail to achieve early molecular response. Poster session presented at the meeting of NDLR. 2018 Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of APG Student Awards. 2018 Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification of ruxolitinib resistance mutations in Pro-B cells driven by a high-risk JAK2 fusion in B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of ASMR. 2018 Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and Characterisation of Ruxolitinib Resistant Mutations in JAK2-rearranged B-cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of AGTA. 2018 Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification of mutations that cause ruxolitinib resistance in Pro-B cells driven by a high-risk B-ALL JAK2-fusion.. Poster session presented at the meeting of ANZCHOG. 2018 Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of SAHMRI Scientific Seminar. 2018 Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of EMBL Australia Postgraduate Symposium. 2017 McClure, B. J., Heatley, S. L., Kok, C., Sadras, T., An, J., Quek, K., . . . White, D. L. (2017). EP300-ZNF384 is a recurrent fusion gene with distinct gene expression in adolescent/young adult pre-B-ALL patients. Poster session presented at the meeting of ANZCHOG. 2017 Heatley, S. L., Sadras, T., Kok, C., Nievergall, E., Quek, K., Dang, P., . . . White, D. L. (2017). High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk-Adapted Treatment. Poster session presented at the meeting of ANZCHOG. 2017 Asari, K., Sadras, T., Srihari, S., Fitter, S., An, J., Zannettino, A. C., . . . White, D. L. (2017). in vitro Modelling of Ph-like ALL Fusions Uncovers Novel Kinase-domain Mutations as a Mode of TKI-resistance and Potential Consequence of Targeted TKI Therapy. Poster session presented at the meeting of ANZCHOG. 2017 Heatley, S., Sadras, T., Kok, C., Nievergall, E., Quek, K., Dang, P., . . . White, D. (2017). High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Poster session presented at the meeting of Abstracts of the 57th Annual Meeting of the American Society of Hematology, as published in Blood. Orlando, FL: American Society of Hematology.
WoS22017 Downes, C. E., McClure, B. M., Heatley, S. H., Sadras, T. S., Hughes, T. H., Kok, C. K., . . . White, D. W. (2017). Identification and cloning of a novel GOLGA4-JAK2 fusion from an adult patient with B-cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Poster session presented at the ASMR SA Scientific Meeting. Adelaide. 2016 Kok, C. H., Watkins, D., Wang, J., Saunders, V., Goyne, J., Pagani, I., . . . White, D. (2016). HIGH GENE EXPRESSION OF HIST1H2AG AND HIST1H4A REDUCES IMATINIB UPTAKE INTO CML CELLS AND PREDICTS POOR RESPONSE TO FRONTLINE IMATINIB THERAPY. Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. 2016 Asari, K., Heatley, S., Leclercq, T., Fitter, S., Kok, C. H., Zannettino, A., . . . White, D. L. (2016). Investigating Modes of Therapeutic Resistance via In Vitro Modelling of TKI-resistant High-Risk Philadelphia-chromosome-positive and Philadelphia-chromosome-like Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Poster Session. Adelaide, SA. 2016 Kok, C. H., Watkins, D., Wang, J., Saunders, V., Goyne, J., Pagani, I. S., . . . White, D. L. (2016). High Gene Expression of hist1h2ag and hist1h4a Reduces Imatinib Uptake into CML Cells and Predicts Poor Response to Frontline Imatinib Therapy. Poster session presented at the meeting of Poster Session. Melbourne, VIC. 2016 Heatley, S., Sadras, T., McClure, B., Kok, C. H., Dang, P., Nievergall, E., . . . White, D. L. (2016). The Incidence of Ph-like Acute Lymphoblastic Leukaemia (ALL) Increases with Age and is Characterised by Poor Outcome. Poster session presented at the meeting of Poster Session. Melbourne, VIC. 2016 Pagani, I. S., Kok, C. H., Wang, J., Saunders, V., Van der Hoek, M., Heatley, S., . . . Ross, D. (2016). Mitochondrial DNA Mutations at Diagnosis are Linked to Response in TKI treated Chronic Myeloid Leukaemia Patients. Poster session presented at the meeting of Poster Session. Melbourne, VIC. 2016 Lu, L., Saunders, V., Kok, C. H., Leclercq, T., Hughes, T., & White, D. L. (2016). Modelling Ponatinib Resistance In BCR-ABL1+ Cell Lines: Implications For Ponatinib Therapy. Poster session presented at the meeting of Poster Session. Adelaide, SA. 2016 Heatley, S., Sadras, T., kok, C., Venn, N., Revesz, T., Osborn, M., . . . White, D. L. (2016). Australian Children with Ph-like ALL enrolled to ANZCHOG ALL8 had a high prevalence of relapse despite risk adapted treatment. Poster session presented at the meeting of CLS SCIENTIFIC PROGRAMME, Refractory Leukemia and Miscellaneous. Athens. 2016 Sadras, T., Heatley, S., Dang, P., Kok, C., Quek, K., Nievergall, E., . . . White, D. L. (2016). A nine-gene signature defines 2 groups of CRLF2 rearranged B-ALL patients with distinctive genetic features. Poster session presented at the meeting of .. Athens. 2016 Pagani, I. S., Kok, C., Saunders, V., Goyne, J., McLean, J., Vanderhoek, M., . . . Ross, D. (2016). The genomic landscape of mitochondrial DNA mutations in chronic myeloid leukaemia. Poster session presented at the meeting of .. Barcelona, Spain. 2016 Sadras, T., Heatley, S., Kok, C., Quek, K., Dang, P., Nievergall, E., . . . White, D. L. (2016). CRLF2 rearranged B-ALL cases with a Ph-like gene signature are enriched for JAK2 mutations. Poster session presented at the meeting of .. Noosa, QLD. 2016 Lu, L., Saunders, V., Kok, C., Leclercq, T., Hughes, T., & White, D. (2016). Modelling ponatinib resistance in BCR-ABL1+ cell lines: implications for ponatinib therapy. Poster session presented at the meeting of New Directions in Leukaemia Research 2016. Noosa, QLD. 2016 McClure, B., Heatley, S., Sadras, T., Nievergall, E., Kok, C., Dang, P., . . . White, D. L. (2016). Identification of a significantly high prevalence of relapse in Australian children with Ph-like ALL. Poster session presented at the meeting of .. Noosa, QLD. 2016 Pagani, I., Kok, C., Saunders, V., Goyne, J., McLean, J., Vanderhoek, M., . . . White, D. L. (2016). Do mitochondrial mutations in chronic myeloid leukaemia identify a pre-leukemic clone?. Poster session presented at the meeting of .. Noosa, QLD. 2014 Nievergall, E., Reynolds, J., Kok, C. H., Watkins, D., Biondo, M., Busfield, S. J., . . . Hughes, T. P. (2014). High plasma levels of TGF-α and IL-6 at diagnosis predict early molecular response failure and transformation in CML. Poster session presented at the meeting of Abstract of presentation to 56th ASH Annual Meeting, published in Blood. San Francisco, California: American Society of Hematology.
WoS12014 Maung, K. Z., Gray, J. X., Leo, P. J., Bassal, M., Brown, A. L., Bray, S. C., . . . Gonda, T. J. (2014). Whole Exome Sequencing of Acute Myeloid Leukaemia Patients Identifies Somatic and Germline Mutations in Fanconi Anaemia Genes. Poster session presented at the meeting of BLOOD. San Francisco, CA: AMER SOC HEMATOLOGY. 2014 Lu, L., Saunders, V., Kok, C. H., Leclercq, T., Hughes, T. P., & White, D. L. (2014). Modeling Ponatinib Resistance in BCR-ABL1+ Cell Lines: Implications for Ponatinib Resistance in TKI-Resistant and TKI-naive Patients. Poster session presented at the meeting of BLOOD. AMER SOC HEMATOLOGY. 2013 Wang, J., Kok, C. H., D'Andrea, R. J., Hughes, T. P., & White, D. L. (2013). Role Of Peroxisome Proliferator-Activated Receptor Gamma (PPAR gamma) and Its Ligands In The Regulation Of Functional OCT-1 Activity In CML Cells. Poster session presented at the meeting of BLOOD. New Orleans, LA: AMER SOC HEMATOLOGY.
2012 D'Andrea, R. J., Perugini, M., Diakiw, S. M., Kok, C. H., Salerno, D., Cummings, N., . . . Lewis, I. D. (2012). Methylation of the Proximal Promoter of GADD45A Is Common in Acute Myeloid Leukemia and Is Associated with Poor Survival. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
2012 Watkins, D. B., Kok, C. H., D'Andrea, R. J., Hughes, T. P., & White, D. L. (2012). Global DNA methylation analysis identifies key pathway differences between poor (low OCT-1 activity) and standard risk CP-CML patients at diagnosis. Poster session presented at the meeting of “Abstracts of the 54th Annual Meeting and Exposition of the American Society of Hematology, as published in Blood. Atlanta, GA: America Society of Hematology. 2011 Sadras, T., Perugini, M., Ramshaw, H., Salerno, D., Kok, C., Lewis, I., . . . D'Andrea, R. (2011). IL-3 REGULATES B-CATENIN IN MYELOID CELLS AND ENFORCED EXPRESSION OF B-CATENIN REDUCES THE DEPENDENCY ON IL-3 FOR SURVIVAL. Poster session presented at the meeting of EXPERIMENTAL HEMATOLOGY. ELSEVIER SCIENCE INC.
-
Memberships
Date Role Membership Country 2016 - ongoing Member American Society of Hematology United States 2013 - 2021 Member European Hematology Association Netherlands
Connect With Me
External Profiles
